LP-50 (Intravesical)

For Non-Muscle Invasive Bladder Cancer

Proprietary Asset

Proprietary Asset

Proprietary Asset

Pre-clinical

Pre-clinical

Pre-
clinical

IND-Enabling

IND-Enabling

IND-Enabling

Phase 1

Phase 1

Phase
1

Phase 2

Phase 2

Phase
2

Phase 3

Phase 3

Phase
3

LP-50 (Intravesical)

Bladder cancer

LP-50 (Intravesical)

Bladder cancer

LP-50 (Intravesical)

Bladder cancer

About Pipeline

LP-50 is an intravesical formulation for local, intravesical PD-1 (i.e. checkpoint) inhibition, intended for the treatment of non muscle invasive bladder cancer (NMIBC).

Intravesical immunotherapy presents a promising avenue for bladder cancer treatment, offering the potential for increasing efficacy while minimizing systemic toxicity.

  • Lipella Pipeline

  • LP-50 | For Non-Muscle Invasive Bladder Cancer

  • Lipella Pipeline

  • LP-50 | For Non-Muscle Invasive Bladder Cancer

  • Lipella Pipeline

  • Lipella Pipeline

  • LP-50 | For Non-Muscle Invasive Bladder Cancer

  • Lipella Pipeline

  • LP-50 | For Non-Muscle Invasive Bladder Cancer

  • Lipella Pipeline